Huguet F, Cayuela JM, Cambier N, et al. - Among 183 patients receiving nilotinib as first-line therapy for chronic myeloid leukaemia in chronic phase (CML-CP), researchers assessed molecular response, safety, quality of life (QoL) and treatment adherence in daily clinical practice in this observational, prospective investigation. Following 24 months of treatment, a major molecular response was achieved by 95·5% and uMR⁴ [defined as an undetectable molecular disease with 4-log molecular response sensitivity (≥ 10,000 ABL1 transcripts)] was achieved by 32·1% of 112/122 patients (91·8%) who had a molecular evaluation. A total of 94/122 patients (77·0%) completed the Morisky Green Levine Medication Adherence Scale, of those, a satisfactory level of treatment adherence was achieved by 89·4%. At baseline, good patients’ QoL was reported, which remained stable during the observation period. Overall, nilotinib was suggested as a valuable first-line treatment choice for CML-CP patients in this French nationwide cohort study.